Author:
Bayat Mokhtari Reza,Baluch Narges,Ka Hon Tsui Micky,Kumar Sushil,S. Homayouni Tina,Aitken Karen,Das Bikul,Baruchel Sylvain,Yeger Herman
Funder
James Birrell Neuroblastoma Fund
The Hospital for Sick Children
Canadian Cancer Society Research Institute
Rally Foundation
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference67 articles.
1. Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2015;62(1):225–56.
2. Dungwa JV, Hunt LP, Ramani P. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Hum Pathol. 2012;43(10):1651–60.
3. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylaseinhibitors. Nat Rev Drug Discov. 2006;5(9):769-84.
4. Ngamphaiboon N, Dy GK, Ma WW, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Invest New Drugs. 2015;33(1):225–32.
5. Gore S: MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. National Cancer Institute (NCI).2016; NCT00101179.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献